Search research articles
Contact Us
Filters
Showing results (21-30 of 40) with videos related to
Page
of 4
Sort By:
The Lancet. Oncology
|
September 5, 2020
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer
Nick Pavlakis, Kohei Shitara, Katrin Sjoquist, et al.
BMC Cancer
|
August 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, et al.
Clinical Colorectal Cancer
|
January 8, 2025
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Matthew E Burge, David Espinoza, Katrin Marie Sjoquist, et al.
Cellular & Molecular Immunology
|
May 10, 2023
CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4<sup>+</sup> T cells
Yuwei Hao, Bahar Miraghazadeh, Rochna Chand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Nick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
BMC Cancer
|
February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
BMJ Open
|
May 15, 2023
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study
Benjamin Y Kong, Hao-Wen Sim, Anna K Nowak, et al.
JTO Clinical and Research Reports
|
January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2015
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A Chantrill, Adnan M Nagrial, Clare Watson, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 40) with videos related to
Sort By:
Page
of 4
The Lancet. Oncology
|
September 5, 2020
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer
Nick Pavlakis, Kohei Shitara, Katrin Sjoquist, et al.
BMC Cancer
|
August 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, et al.
Clinical Colorectal Cancer
|
January 8, 2025
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Matthew E Burge, David Espinoza, Katrin Marie Sjoquist, et al.
Cellular & Molecular Immunology
|
May 10, 2023
CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4<sup>+</sup> T cells
Yuwei Hao, Bahar Miraghazadeh, Rochna Chand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Nick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
BMC Cancer
|
February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
BMJ Open
|
May 15, 2023
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study
Benjamin Y Kong, Hao-Wen Sim, Anna K Nowak, et al.
JTO Clinical and Research Reports
|
January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2015
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A Chantrill, Adnan M Nagrial, Clare Watson, et al.
Page
of 4